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ABSTRACT – Familial encephalopathy with neuroserpin inclusion bod-
ies (FENIB) is a conformational proteinopathy characterised by neuronal
inclusion bodies composed of the serine protease inhibitor (SERPIN), neu-
roserpin. Presentingclinically as a familial dementia-epilepsy syndrome, the
molecular mechanism of the pathogenic abnormalities in neuroserpin has
been characterised at atomic resolution. There is a remarkable genotype-
phenotype correlation between the degree of molecular destabilisation of
the several variants of the neuroserpin protein, their propensity to self-
associate and the age of onset of the dementia-epilepsy complex. As with
other serpinopathies there appears to be a mix of cell-autonomous toxicity,
due to neuronal accumulation of neuroserpin, and non-cell autonomous
toxicity, caused by loss of protease inhibition, in this case the dysregulated
protease is likely to be tissue plasminogen activator (tPA). FENIB should
e myoclonic epilepsy and dementia
ory of neuropsychiatric disease.
otease inhibitor, conformational dis-
ial progressive myoclonic epilepsy,
sies
inhibitors (serpins) are a large super-
family of proteins that employ
a conserved molecular mecha-
nism for the inhibition of a wide
range of proteases. Mutations may
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particularly where there is family hist
Key words: serpins, serpinopathy, pr
ease, neuroserpin, dementia, famil
FENIB, progressive myoclonus epilep
Familial encephalopathy with neu-
roserpin inclusions bodies (FENIB)
has been identiﬁed as a cause of
pre-senile dementia with frontal
symptoms as well as progressivepileptic Disord, Vol. 18, Supplement 2, September 2016 S103
orrespondence:
amian C. Crowther
epartment of Genetics,
niversity of Cambridge,
owning Street, Cambridge, CB2 3EH,
nited Kingdom
damian.crowther@azneuro.com>
myoclonic epilepsy (Minassian
et al., 2016). In affected individuals,
mutated neuroserpin accumulates
in neuronal inclusions (Collins bod-
ies). FENIB is due to mutations
in the SERPINI1 gene located on
chromosome 3q26. Serine protease
render serpins prone to polymeri-
sation, i.e. ordered aggregation, in
the endoplasmic reticulum of the
synthetic Acell. In the case of neu-
roserpin (NS), a neuronal protein,
this aggregation causes gain-of-
function neuronal dysfunction
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hat is thought to underpin the neurological mani-
estations. NS also inhibits tPA and, in this way, is
hought to regulate the sensitivity of neurones to glu-
amatergic excitatory neurotransmission at the NMDA
N-methyl-D-aspartate) receptor. The epileptic com-
onent of FENIB may be due to dysfunction of the
S/tPA pathway.
euroserpin (NS) is a member of the serine protease
nhibitor, or serpin, superfamily and has sequence and
tructural homologies to the archetype 1-antitrypsin.
t the molecular level, serpins are composed of 9 -
elices, 3 -sheets (A to C) and an exposed mobile
eactive centre loop (RCL). The RCL typically contains
0 residues that act as a pseudo-substrate for the tar-
et protease (Elliott et al., 1996; Ryu et al., 1996). The
ain role of NS is to regulate the plasmin prote-
lytic pathway, in particular by inhibiting tissue-type
lasminogen activator (tPA). In this regard, NS plays
hysiological roles in the development of the central
ervous system (Seeds et al., 1999), in learning and
emory and also in such pathological events as stroke
Cole et al., 2007) and epilepsy (Qian et al., 1993).
umerous mutations in human serpins have been
inked to a wide range of diseases; examples include
mphysema, angioedema, anddementiawith progres-
ive myoclonus epilepsy, resulting from mutations in
1-antitrypsin, C1-inhibitor, and neuroserpin, respec-
ively. Direct toxicity is invariably a consequence of the
ntracellular accumulation of serpin aggregates that
re termed polymers, and may result in death of the
ynthetic cell. In the case of neuroserpin, cytotoxicity
s seen exclusively in neurons of the central nervous
ystem. There may also be associated loss-of-function
ffects caused by the deregulated hyperactivity of the
arget proteases and this may underpin the devel-
pment of epilepsy in patients carrying neuroserpin
ariants. To date, only a few families and exception-
lly rare non-familial cases of progressive myoclonic
pilepsy linked to the SERPINI1 gene have been
escribed. Age at onset is between 13 and 60 years and
he disorder is severe with rapid loss of autonomy and
remature death.
athophysiology of neuroserpin-related
isease
euroserpin was ﬁrst identiﬁed as an axonally-
ecreted glycoprotein in the conditioned medium of104
mbryonic chick dorsal root ganglia cells (Stoeckli et
l., 1989; Osterwalder et al., 1996). In mammals it is
xpressed in the central and peripheral nervous sys-
em, predominantly in neurons (Hastings et al., 1997;
sterwalder et al., 1998) where it can inhibit a number
f trypsin-like enzymes, including thrombin and plas-
in (Osterwalder et al., 1998), however, subsequent
(
r
o
a
i
g
atudies indicate thatPA is themainphysiological target.
ccordingly, the highest levels of NS are found in parts
f the nervous system that have thehighest expression
f tPA mRNA and protein (Krueger et al., 1997).
hile not all serpins interact with proteases, those
uch as neuroserpin, which have retained inhibitory
ctivity, employ a highly conserved molecular mecha-
ism. The sequence of events that results in inhibition
egins with the serpin’s RCL (labelled in red in
gure 1M) entering the active site of the cognate pro-
ease, initially behaving as a substrate. The enzyme
nd serpin form a transient intermediate called the
ichaelis complex (Ye et al., 2001) which precedes the
leavage of the RCL at a speciﬁc position, termed the
1-P1’ bond. This leads to the release of the P1 residue
nd the formation of an ester bond between the C-
erminal portion of the serpin and the protease. At
his stage, however, further hydrolysis, that would oth-
rwise release cleaved serpin and active protease, is
reventedbyaprofoundconformational change in the
erpin (Wright & Scarsdale, 1995). This transition from
“stressed to relaxed” form occurs as the protease-
ttached remainder of the RCL inserts as a -strand in
he main -sheet A of the serpin core. This insertion
s highly energetically favourable and violently ﬂips
he enzyme from the upper to the lower pole of the
erpin (Huntington et al., 2000), causing steric denat-
ration and inactivation of the protease. Permanent
estruction of the protease is subsequently achieved
y third-party proteolysis of those domains of the tar-
et protease that have been rendered unstructured
Huntington et al., 2000). Experimentally, the enzyme-
erpin complex is relatively stable with a dissociation
ate constant that is an order of magnitude slower
han the association rate (Belorgey et al., 2002). How-
ver, dissociation of the serpin-enzyme complex does
ccur, in which case the released neuroserpin is in the
nactive, cleaved conformation. In contrast, when tPA
s liberated from the complex, it retains its proteolytic
ctivity(Osterwalder et al., 1998).
linical features and
enotype-phenotype correlations
utations in the neuroserpin gene were ﬁrst reported
o cause an autosomal dominant form of pre-senile
ementia (Belorgey et al., 2002), described as famil-
al encephalopathy with neuroserpin inclusion bodiesEpileptic Disord, Vol. 18, Supplement 2, September 2016
FENIB), characterized histologically by unique neu-
onal inclusion bodies and biochemically by polymers
f the neuron-speciﬁc serpin, neuroserpin. These
uthors reported 2 unrelated Caucasian families living
n the United States, carrying 2 different heterozy-
ous mutations (S49P and S52R). In the larger family,
ffected individuals presented clinically around the
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7.igure 1. Molecular models of serpin conformers. M represents
-sheet A in blue. Mutations that destabilize sheet A (typically in
he partial insertion of the reactive loop to form a new strand in s
oop from another serpin to insert forming a serpin dimer (P). T
ay results in large aggregates.
fth decade of life with cognitive decline, includ-
ng deﬁcits in attention and concentration, response
egulation difﬁculties, and impaired visuospatial skills.
emory was also impaired, but to a lesser degree than
s typically seen in individuals with Alzheimer’s dis-
ase. After several years of disease progression, most
ffected individuals were unable to work and eventu-
lly required nursing-home care. The second, much
maller family showed an earlier clinical onset, during
he second or third decade of life. Affected individuals
resented with both epilepsy and progressive cogni-
ive decline and their neuro-histology was dominated
y eosinophilic, PAS-positive intraneuronal inclusions
n the brain. Later on, a small family with 2 affected
iblings featuring progressive myoclonus epilepsy and
ementia was described (Belorgey et al., 2002). The
ffected individuals developed generalized seizures
n adulthood and progressed to status epilepticuspileptic Disord, Vol. 18, Supplement 2, September 2016
ver several years. In addition, they also developed
low speech, diplopia, nystagmus, dysarthria, and
yoclonus in the extremities, with rapidly progres-
ive dementia. Their deceasedmotherwas, reportedly,
imilarly affected.
avis et al. (1999a) reported additional patients with
hedisorder: a 23-year-oldmanwithan8-yearhistoryof
A
w
(
o
i
m
Ictive protease inhibitor with the reactive loop shown in red and
o-called ‘shutter region’ signiﬁed by the red dashed box) allow
A (M*). The consequent opening of the sheet allows the reactive
peated addition of serpins by loop-sheet polymerisation in this
rogressivemyoclonic epilepsy, dementia, tremor, and
ysarthria. The second patient was a 13-year-old girl
ith progressive myoclonus epilepsy with intractable
eizures,myoclonus, anddementia. Shediedat theage
f 19 during status epilepticus. Her father was said to
e ‘mentally deﬁcient’, and a paternal uncle had died
rom epilepsy at the age of 18.
ourﬁnkel-An et al. (2007) subsequently described
small French family with progressive myoclonic
pilepsy associated with a frontal syndrome starting
rom the age of 18 with severe myoclonus, general-
zed tonic-clonic seizures, and absences. The EEG of
ne of the patients showed diffuse slow waves, spikes,
nd spike-wave discharges superimposed on a slow
ackground, with photic sensitivity at around 1 Hz.
erebral MRI revealed cortico-subcortical atrophy.
he patient’s condition progressively worsened and
wallowing difﬁculties were noticed at an early stage.S105
dditionally, cerebellar symptoms andpyramidal signs
ere also present. Cognitive deterioration was severe
Mini-Mental Status Examination score: 12/30). Signs
f frontal dysfunction were observed (emotional labil-
ty, distractibility, and poor performance on sequential
otor tests)with sparingof long-termexplicitmemory.
n another affected relative, who died at the age of 33,
Journal Identiﬁcation = EPD Article Identiﬁcation = 0847 Date: October 4, 2016 Time: 2:49 pm
S
B.D. Roussel, et al.
Table 1. Various mutations in the neuroserpin gene cause onset of dementia and myoclonic epilepsy at a wide
range of ages. The most aggregation-prone neuroserpin variants in vitro cause juvenile forms of FENIB while
less destabilizing mutations are not penetrant until the seventh decade. Histologically, patients with early onset
disease exhibit a higher burden of cortical neuroserpin inclusions (+ through to ++++).
Mutation Onset (years) Clinical ﬁndings Inclusions
S49P 45-63 Dementia and terminal seizures +
S52R 20-40 Myoclonus, Dementia ++
L47P 20-30 Progressive myoclonus epilepsy +++
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7.H338R 15 Prog
G392E 13 Prog
G392R 8 Epile
ymptoms were similar and were ﬁrst noticed when
he was 18. Behavioural problems, depression, and
rontal dysfunction were noticed. Epilepsy was drug-
esistant and she experienced, during the course of
he disorder, two episodes of status epilepticus. She
ecame mute and bedridden and died of inhalation
neumonia at the age of 33. In these patients, a het-
rozygous S52R missense mutation at position 273 in
xon 2 was detected, the same as in the two families
rom the United States.
few non-familial cases have been also described.
outelier et al. (2008) reported an 11-year-old girl who
ad had normal development until 8 years of age,
hen she developed a rapidly-progressive symptoma-
ology, including aggressive behaviour, intellectual
ecline, psychic seizures, and subtle seizureswith eye-
idmyoclonus. The EEGwas suggestiveof epilepsywith
ontinuous spike-and-waves during slow-wave sleep.
his patient was the ﬁrst person identiﬁed with the
392R mutation in neuroserpin that resulted in severe
uvenile phenotype and had accordingly appeared
e novo. Hagen et al. (2011) more recently reported
n additional sporadic patient with progressive
yoclonus epilepsy and declining mental status start-
ng in adulthood. Generalized seizures occurred early
ith myoclonus and progressive gait disturbances.
euroimaging revealed mild atrophy and multiple
eriventricular white matter lesions, consistent with
emyelination. The course was one of progressive
ecline with death occurring at the age of 34. Genetic
nalysis revealed a nucleotide substitution, resulting106
n a proline to leucine amino acid substitution (L47P).
he genotype-phenotype correlations are remarkably
trong, with mutations causing increasingly severe
linical features in the following order: S49P, S52R,
47P, H338R, G392E and G392R (table 1). In general,
ncreasing clinical severity is characterized by earlier
nset of the symptom and an increasing contribution
m
o
c
a
i
a
ave myoclonus epilepsy +++
ve myoclonus epilepsy, chorea ++++
ith slow wave sleep ++++
rom the epileptic component of the syndrome. More
peciﬁcally, individuals with the S49P mutation have
iffuse small intraneuronal inclusions of neuroserpin
ith an onset of dementia between the ages of 45 and
0 (Davis et al., 1999a; Davis et al., 1999b; Bradshaw
t al., 2001). People with the S52R, L47P and H338R
ariants have larger and more numerous intraneu-
onal inclusions associated with progressively earlier
nset of symptoms, during early adulthood (S52R,
47P) and adolescence (H338R) (Hagen et al., 2011;
iranda et al., 2008). In the most severe cases, caused
y the most polymerogenic mutations, namely G392R
nd G392E, the patients exhibit the earliest onset of
ymptoms, with profound intellectual decline dur-
ng childhood associated with severe, uncontrolled
pilepsy (Coutelier et al., 2008). While FENIB is a
are disease, with only a few known kindreds world-
ide, diagnosis should be considered in patients that
resent with a frontal-type dementia combined with
pilepsy, particularly when eosinophilic inclusions are
een on brain biopsy or at post-mortem.
he pathological polymerisation
f neuroserpin variants results in FENIB
hese remarkable genotype-phenotype correlations
hat are evident in the clinic are mirrored by the
iophysical and biochemical properties of the vari-
nt NS proteins. Under physiological conditions, the
ate of aggregation of the least clinically-aggressive NSEpileptic Disord, Vol. 18, Supplement 2, September 2016
utant, S49P, is more than 10 times higher than that
f the wild type protein, whereas the association rate
onstant for tPA is essentially unchanged (Belorgey et
l., 2002). The next most severe mutation, S52R, results
n a further tenfold increase in the polymerization rate
nd the loss of effective tPA inhibition (Belorgey et
l., 2004). Thereafter, the aggregation rate becomes so
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7.igh as to be practically immeasurable. In the classic
odel of serpin polymerisation, proposed by Carrell
nd Lomas (2002), the functional changes in NS are
ll caused by the progressive destabilization of the
ey structural element, termed -sheet A, which forms
he core of NS (ﬁgure 1). This structural perturbation
avours the incorporation of the RCL from a second
S molecule over the physiological process of intra-
olecular RCL insertion that occurs during protease
nhibition (Daviset al., 2002). An initial loop-sheet poly-
erizationevent yields aNSdimer that retains apatent
-sheet A at one end and a destabilized RCL at the
ther. Such a dimer is competent to undergo further
oop-sheet polymerization to form trimers andeventu-
lly higher-order polymers. Recently, Huntington and
olleagues have proposed alternative mechanisms for
olymerization that require a more signiﬁcant domain
wap between the serpins in a chain (Sado et al.,
009; Huntington & Whisstock, 2010; Belorgey et al.,
011; Singh & Jairajpuri, 2011; Yamasaki et al., 2011).
n either case, the NS polymers gradually become
ntangled in the neuronal endoplasmic reticulum (ER)
nd form inclusions, known as Collins bodies. This
henomenon of aggregation or ‘polymerization’ has
een described in other serpins such as 1-antitrypsin
here it results in hepatocyte inclusions and liver dis-
ase (Lomas et al., 1992; Elliott et al., 1996; Huntington
t al., 1999). The observation that FENIB was caused
y NS mutations (S49P and H338R) that are structurally
omologous to substitutions in 1-antitrypsin, which
lso lead to polymerization (S53F and H334D, respec-
ively) (Lomas et al., 1993), argues strongly in favour
f a shared molecular mechanism. This was conﬁrmed
y the ﬁnding that the neuronal inclusion bodies of
ENIB were formed by polymers of NS with identical
orphology to the polymers of mutant 1-antitrypsin
resent in hepatocytes from a childwith 1-antitrypsin
eﬁciency-related cirrhosis (Davis et al., 1999a; Carrell
Lomas, 2002).
issecting the pathological
echanisms of the dementing
nd epileptic components of FENIB
he ER-resident inclusions (Miranda et al., 2004) in
he neurones of individuals expressing NS variants
re likely to represent the toxic gain-of-function that
esults in this dominantly-inherited neurodegenera-pileptic Disord, Vol. 18, Supplement 2, September 2016
ive syndrome. Serpin polymerisation exerts a stress
n the cell that differs in important ways from other
roteinopathies. In most cases, misfolding of proteins
n the ER results in activation of the unfolded protein
esponse (UPR). However, the native-like structure of
erpin polymers results in a distinct signalling pathway
alled the ER overload response (Davies et al., 2009).
C
F
b
e
eNeuroserpinosis
his ER overload response activates NF-B by a path-
ay that is dependent on raised cytoplasmic Ca2+
evels. ER-associated degradation or ERAD is involved
n the degradation of mutant NS and may be able
o degrade the polymers (Ying et al., 2011), whereas
utophagy is more important in the bulk turnover of
oth wild type and mutant NS (Kroeger et al., 2009). In
he presence of polymerogenic mutations in serpins,
nd with increasing age, these mechanisms are over-
helmed and retention of polymers in the ER leads to
ell death. This is apparent in the ﬂy model of FENIB
here the accumulation of intracellular polymers is
ssociated with locomotor deﬁcits where there was
correlation between the severity of the behavioural
eﬁcits and the degree of polymer accumulation
Miranda et al., 2008).
hile the intraneuronal accumulationofNS inclusions
ay underpin the dementia seen in FENIB, there is evi-
ence that other mechanisms may also contribute to
he epileptic propensity of thesepatients. In particular,
t is notable that epilepsy is rarely seen when normal
evels of tPA inhibitory activity are present, as is the
ase for wild type and S49P NS. This has been recently
ighlighted in relation tostroke,wherepatients throm-
olyzed with recombinant tPA present a higher level
f seizures (Alvarez et al., 2013). When tPA inhibition is
ost (for example, for the S52R and 392 mutants) then
pilepsy becomes the major clinical feature (Davis et
l., 2002). Notably, neuroserpin is able to dampen neu-
onal sensitivity to excitotoxic stimuli by regulating tPA
ctivity (Yepes et al., 2000; Yepes et al., 2002; Wu et al.,
010). This effect appears to be mediated by the tPA-
ediated proteolytic cleavage of the NR1 subunit of
he NMDA receptor that increases the functioning of
his excitatory glutamate receptor (ﬁgure 2) (Nicole et
l., 2001; Fernandez-Monreal et al., 2004; Samson et al.,
008; Baron et al., 2010).
xcess glutamatergic neurotransmission is also a
otent cause of epilepsy (reviewed in Vincent & Mulle
2009]) and increased NMDA signalling in response to
ysregulated tPA activity could contribute to FENIB.
ndeed, co-injection of neuroserpin with kainate into
he hippocampus of the mouse attenuated the spread
f consequent epileptic activity when compared to
o-injection of kainate with vehicle alone (Yepes et
l., 2002). These data suggest a role for tPA in seizure
pread in epilepsy and support the use of NS or others
PA inhibitors as a potential therapy.S107
onclusion
amilial encephalopathy with neuroserpin inclusion
odies is a recently described neurodegenerative dis-
ase that is responsible for progressive myoclonic
pilepsy and/or pre-senile dementia. Serpinopathies
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7.igure 2. TheNMDA receptormediates the inﬂux of calcium into
he NR1 subunit (triangle) of the receptor and, as a consequenc
PA, neuroserpin is thought to protect neurons from the toxic co
re unique among conformational diseases because
hey form native-like aggregates or polymers in the
R of synthetic cells. Serpin variants accumulate as
nclusion bodies and thus activate the ER-overload
esponse. It appears that this gain-of-function toxicity
s responsible for the neuronal dysfunction and death
hat underpins dementia in FENIB. The evidence is less
lear as to whether similar gain-of-toxicity is the cause
f the epilepsy in FENIB or whether this results from
ysfunction of the NS/tPA system. The relative impor-
ance of these two mechanisms has yet to be clearly
lucidated. To date, genetic analysis of the SERPINI1
ene shouldbeperformed inpatientswith adult-onset
MEandearly-onset, rapidlyprogressivecognitivedys-
unction or predominantly frontal dementia. 
isclosures.
one of the authors have any conﬂict of interest to disclose.
he present manuscript is part of a Epileptic Disorders/
ariani Foundation supplement on Progressive Myoclonus
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